Psychedelic therapeutics in psychiatric conditions
Neuropsychopharmacology – January 16, 2026
Source: OpenAlex
Summary
The burgeoning interest in psychedelic therapies has sparked hundreds of clinical trials, yet no approved treatments exist for psychiatric conditions. Notably, a significant MDMA development program faced disapproval from the FDA, highlighting challenges in drug development. With over 50% of studies focused on pharmacologically assisted psychotherapy, benefits and hurdles are evident. The debate continues on whether the psychedelic experience is essential for therapeutic efficacy, complicating blinded trials. Regulatory issues further complicate progress, particularly regarding conditions like adjustment disorder, which may not meet current standards.
Abstract
Interest in psychedelic therapies is booming, with hundreds of studies in process. Despite the interest, there are no approved psychedelic treatments for any psychiatric condition. Further, the one large-scale development program using MDMA that reached the FDA was disapproved by the agency for reasons that could apply to clinical trials for classical psychedelics. We review the definitions of psychedelics, the current status of psychedelic therapies, conditions targeted, compounds under investigation, and the research/clinical strategies employed. Some treatment interventions include pharmacologically assisted psychotherapy, with both benefits and challenges associated with this strategy. There is debate about whether the psychedelic experience is a required fundamental element for therapeutic potential with the induced psychedelic state, rendering blinded clinical trials challenging. We address current societal issues, such as the deregulation of formerly illegal substances in some areas, that may affect development decisions. Our review also considers regulatory issues, including alternatives to blinded trials and whether some therapeutic targets, such as adjustment disorder, may pose hurdles if current regulatory standards are applied to these trials. The interest in psychedelic treatment is considerable, although the path forward has some complexities.